Eris Lifesciences Limited (NSE: ERIS.NS) Stock Competitors & Peer Comparison

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUNPHARMA.NS trades at ₹1,941.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUNPHARMA.NS's P/E ratio is 37.71. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, ERIS.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check SUNPHARMA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUNPHARMA.BO trades at ₹1,941.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUNPHARMA.BO's P/E ratio is 38.06. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, ERIS.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check SUNPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, DIVISLAB.NS has a market cap of 1.9T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while DIVISLAB.NS trades at ₹7,248.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas DIVISLAB.NS's P/E ratio is 74.64. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to DIVISLAB.NS's ROE of +0.16%. Regarding short-term risk, ERIS.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check DIVISLAB.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, DIVISLAB.BO has a market cap of 1.9T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while DIVISLAB.BO trades at ₹7,246.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas DIVISLAB.BO's P/E ratio is 71.63. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to DIVISLAB.BO's ROE of +0.16%. Regarding short-term risk, ERIS.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check DIVISLAB.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, TORNTPHARM.NS has a market cap of 1.7T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while TORNTPHARM.NS trades at ₹4,961.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas TORNTPHARM.NS's P/E ratio is 74.34. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to TORNTPHARM.NS's ROE of +0.26%. Regarding short-term risk, ERIS.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check TORNTPHARM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, TORNTPHARM.BO has a market cap of 1.7T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while TORNTPHARM.BO trades at ₹4,959.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas TORNTPHARM.BO's P/E ratio is 75.26. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to TORNTPHARM.BO's ROE of +0.26%. Regarding short-term risk, ERIS.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check TORNTPHARM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ZYDUSLIFE.NS trades at ₹1,108.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ZYDUSLIFE.NS's P/E ratio is 23.04. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ZYDUSLIFE.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ZYDUSLIFE.BO trades at ₹1,108.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ZYDUSLIFE.BO's P/E ratio is 23.13. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, ERIS.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ZYDUSLIFE.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while LUPIN.BO trades at ₹2,369.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas LUPIN.BO's P/E ratio is 18.60. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, ERIS.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check LUPIN.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while LUPIN.NS trades at ₹2,370.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas LUPIN.NS's P/E ratio is 18.61. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, ERIS.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check LUPIN.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while MANKIND.NS trades at ₹2,507.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas MANKIND.NS's P/E ratio is 50.75. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to MANKIND.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check MANKIND.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while MANKIND.BO trades at ₹2,505.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas MANKIND.BO's P/E ratio is 51.05. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to MANKIND.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check MANKIND.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, DRREDDY.NS has a market cap of 971.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while DRREDDY.NS trades at ₹1,151.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas DRREDDY.NS's P/E ratio is 22.68. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to DRREDDY.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check DRREDDY.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, DRREDDY.BO has a market cap of 971.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while DRREDDY.BO trades at ₹1,152.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas DRREDDY.BO's P/E ratio is 22.68. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check DRREDDY.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AUROPHARMA.NS has a market cap of 881.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AUROPHARMA.NS trades at ₹1,532.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AUROPHARMA.NS's P/E ratio is 25.39. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check AUROPHARMA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AUROPHARMA.BO has a market cap of 880.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AUROPHARMA.BO trades at ₹1,531.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AUROPHARMA.BO's P/E ratio is 25.38. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check AUROPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, LAURUSLABS.NS has a market cap of 865B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while LAURUSLABS.NS trades at ₹1,601.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas LAURUSLABS.NS's P/E ratio is 97.28. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to LAURUSLABS.NS's ROE of +0.18%. Regarding short-term risk, ERIS.NS is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check LAURUSLABS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, LAURUSLABS.BO has a market cap of 865B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while LAURUSLABS.BO trades at ₹1,602.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas LAURUSLABS.BO's P/E ratio is 96.93. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to LAURUSLABS.BO's ROE of +0.18%. Regarding short-term risk, ERIS.NS is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check LAURUSLABS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ALKEM.BO has a market cap of 673.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ALKEM.BO trades at ₹5,635.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ALKEM.BO's P/E ratio is 29.26. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ALKEM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ALKEM.NS has a market cap of 673.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ALKEM.NS trades at ₹5,633.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ALKEM.NS's P/E ratio is 34.68. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ALKEM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GLENMARK.BO has a market cap of 619B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GLENMARK.BO trades at ₹2,193.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GLENMARK.BO's P/E ratio is 45.47. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, ERIS.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check GLENMARK.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GLENMARK.NS has a market cap of 618.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GLENMARK.NS trades at ₹2,192.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GLENMARK.NS's P/E ratio is 35.93. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLENMARK.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, IPCALAB.BO has a market cap of 447.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while IPCALAB.BO trades at ₹1,762.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas IPCALAB.BO's P/E ratio is 49.16. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, ERIS.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check IPCALAB.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, IPCALAB.NS has a market cap of 447.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while IPCALAB.NS trades at ₹1,762.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas IPCALAB.NS's P/E ratio is 38.10. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, ERIS.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check IPCALAB.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AJANTPHARM.NS has a market cap of 421B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AJANTPHARM.NS trades at ₹3,369.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AJANTPHARM.NS's P/E ratio is 39.90. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AJANTPHARM.NS's ROE of +0.25%. Regarding short-term risk, ERIS.NS is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check AJANTPHARM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AJANTPHARM.BO has a market cap of 420.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AJANTPHARM.BO trades at ₹3,366.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AJANTPHARM.BO's P/E ratio is 39.87. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AJANTPHARM.BO's ROE of +0.25%. Regarding short-term risk, ERIS.NS is less volatile compared to AJANTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check AJANTPHARM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVENPHAR.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVENPHAR.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check JBCHEPHARM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, JBCHEPHARM.BO has a market cap of 386.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas JBCHEPHARM.BO's P/E ratio is 52.61. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, ERIS.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check JBCHEPHARM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, EMCURE.NS has a market cap of 356.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while EMCURE.NS trades at ₹1,881.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas EMCURE.NS's P/E ratio is 70.98. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check EMCURE.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, WOCKPHARMA.BO has a market cap of 299.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while WOCKPHARMA.BO trades at ₹1,842.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas WOCKPHARMA.BO's P/E ratio is 140.50. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to WOCKPHARMA.BO's ROE of +0.04%. Regarding short-term risk, ERIS.NS is more volatile compared to WOCKPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check WOCKPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, ERIS.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check PEL.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, PPLPHARMA.BO has a market cap of 240.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while PPLPHARMA.BO trades at ₹181.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas PPLPHARMA.BO's P/E ratio is -154.68. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, ERIS.NS is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check PPLPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, PPLPHARMA.NS has a market cap of 240.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while PPLPHARMA.NS trades at ₹181.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas PPLPHARMA.NS's P/E ratio is -154.78. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, ERIS.NS is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check PPLPHARMA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NEULANDLAB.BO has a market cap of 238.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NEULANDLAB.BO trades at ₹18,570.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NEULANDLAB.BO's P/E ratio is 64.24. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, ERIS.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check NEULANDLAB.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NEULANDLAB.NS has a market cap of 237.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NEULANDLAB.NS trades at ₹18,546.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NEULANDLAB.NS's P/E ratio is 61.84. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, ERIS.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check NEULANDLAB.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GRANULES.NS has a market cap of 206.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GRANULES.NS trades at ₹833.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GRANULES.NS's P/E ratio is 33.56. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, ERIS.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GRANULES.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GRANULES.BO has a market cap of 206.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GRANULES.BO trades at ₹833.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GRANULES.BO's P/E ratio is 33.55. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, ERIS.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GRANULES.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ASTRAZEN.NS has a market cap of 200.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ASTRAZEN.NS trades at ₹8,005.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ASTRAZEN.NS's P/E ratio is 106.73. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, ERIS.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ASTRAZEN.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ASTRAZEN.BO has a market cap of 200.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ASTRAZEN.BO trades at ₹8,000.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ASTRAZEN.BO's P/E ratio is 106.65. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, ERIS.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check ASTRAZEN.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ERIS.BO has a market cap of 194B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ERIS.BO trades at ₹1,398.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ERIS.BO's P/E ratio is 45.36. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ERIS.BO's ROE of +0.18%. Regarding short-term risk, ERIS.NS is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check ERIS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, CAPLIPOINT.NS has a market cap of 187.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while CAPLIPOINT.NS trades at ₹2,467.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas CAPLIPOINT.NS's P/E ratio is 28.99. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to CAPLIPOINT.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check CAPLIPOINT.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, CAPLIPOINT.BO has a market cap of 187.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while CAPLIPOINT.BO trades at ₹2,464.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas CAPLIPOINT.BO's P/E ratio is 32.80. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to CAPLIPOINT.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check CAPLIPOINT.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NATCOPHARM.NS has a market cap of 165B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NATCOPHARM.NS trades at ₹921.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NATCOPHARM.NS's P/E ratio is 12.45. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check NATCOPHARM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NATCOPHARM.BO has a market cap of 164.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NATCOPHARM.BO trades at ₹920.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NATCOPHARM.BO's P/E ratio is 12.42. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, ERIS.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check NATCOPHARM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, COHANCE.BO has a market cap of 159.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while COHANCE.BO trades at ₹417.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas COHANCE.BO's P/E ratio is 82.45. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to COHANCE.BO's ROE of +0.05%. Regarding short-term risk, ERIS.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check COHANCE.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, COHANCE.NS has a market cap of 159.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while COHANCE.NS trades at ₹417.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas COHANCE.NS's P/E ratio is 77.60. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to COHANCE.NS's ROE of +0.05%. Regarding short-term risk, ERIS.NS is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check COHANCE.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, APLLTD.BO has a market cap of 157.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while APLLTD.BO trades at ₹796.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas APLLTD.BO's P/E ratio is 21.24. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check APLLTD.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, APLLTD.NS has a market cap of 156.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while APLLTD.NS trades at ₹797.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas APLLTD.NS's P/E ratio is 21.27. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check APLLTD.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, JUBLPHARMA.NS has a market cap of 152.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while JUBLPHARMA.NS trades at ₹965.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas JUBLPHARMA.NS's P/E ratio is 35.62. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, ERIS.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check JUBLPHARMA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, JUBLPHARMA.BO has a market cap of 152.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while JUBLPHARMA.BO trades at ₹962.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas JUBLPHARMA.BO's P/E ratio is 35.50. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, ERIS.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check JUBLPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ALIVUS.BO has a market cap of 135.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ALIVUS.BO trades at ₹1,101.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ALIVUS.BO's P/E ratio is 24.51. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ALIVUS.BO's ROE of +0.05%. Regarding short-term risk, ERIS.NS is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check ALIVUS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ALIVUS.NS has a market cap of 135.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ALIVUS.NS trades at ₹1,101.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ALIVUS.NS's P/E ratio is 41.01. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, ERIS.NS is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check ALIVUS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GLS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SHILPAMED.NS has a market cap of 118.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SHILPAMED.NS trades at ₹606.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SHILPAMED.NS's P/E ratio is 46.81. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SHILPAMED.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, PGHL.NS has a market cap of 111.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while PGHL.NS trades at ₹6,714.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas PGHL.NS's P/E ratio is 34.10. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, ERIS.NS is more volatile compared to PGHL.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check PGHL.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, PGHL.BO has a market cap of 111.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while PGHL.BO trades at ₹6,723.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas PGHL.BO's P/E ratio is 37.26. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, ERIS.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check PGHL.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, VIYASH.NS has a market cap of 109.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while VIYASH.NS trades at ₹250.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas VIYASH.NS's P/E ratio is 77.92. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check VIYASH.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check CAPPL.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AKUMS.NS has a market cap of 105.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AKUMS.NS trades at ₹687.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AKUMS.NS's P/E ratio is 55.03. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, ERIS.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check AKUMS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, STAR.NS has a market cap of 94B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while STAR.NS trades at ₹1,020.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas STAR.NS's P/E ratio is 16.92. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check STAR.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, STAR.BO has a market cap of 93.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while STAR.BO trades at ₹1,019.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas STAR.BO's P/E ratio is 16.90. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, ERIS.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check STAR.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUDEEPPHRM.NS has a market cap of 93.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUDEEPPHRM.NS trades at ₹825.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUDEEPPHRM.NS's P/E ratio is 95.39. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, ERIS.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUDEEPPHRM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUVEN.BO has a market cap of 71.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUVEN.BO trades at ₹316.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUVEN.BO's P/E ratio is -25.49. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVEN.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SUVEN.NS has a market cap of 71.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SUVEN.NS trades at ₹316.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SUVEN.NS's P/E ratio is -26.20. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, ERIS.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SUVEN.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SPARC.BO has a market cap of 70.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SPARC.BO trades at ₹216.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SPARC.BO's P/E ratio is 4.52. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, ERIS.NS is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check SPARC.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SPARC.NS has a market cap of 70.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SPARC.NS trades at ₹216.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SPARC.NS's P/E ratio is 4.52. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, ERIS.NS is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SPARC.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, FDC.NS has a market cap of 67.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while FDC.NS trades at ₹412.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas FDC.NS's P/E ratio is 26.76. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check FDC.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AARTIPHARM.NS has a market cap of 61.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AARTIPHARM.NS trades at ₹673.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AARTIPHARM.NS's P/E ratio is 23.29. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIPHARM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AARTIPHARM.BO has a market cap of 61.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AARTIPHARM.BO trades at ₹674.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AARTIPHARM.BO's P/E ratio is 32.54. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIPHARM.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SHILPAMED.BO has a market cap of 59.2B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SHILPAMED.BO trades at ₹605.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SHILPAMED.BO's P/E ratio is 48.65. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is more volatile compared to SHILPAMED.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check SHILPAMED.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, INNOVACAP.NS has a market cap of 54.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while INNOVACAP.NS trades at ₹950.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas INNOVACAP.NS's P/E ratio is 44.69. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, ERIS.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check INNOVACAP.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SEQUENT.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, ERIS.NS is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SEQUENT.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ORCHPHARMA.NS has a market cap of 50.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ORCHPHARMA.NS trades at ₹988.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ORCHPHARMA.NS's P/E ratio is 159.45. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, ERIS.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check ORCHPHARMA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, ORCHPHARMA.BO has a market cap of 50.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while ORCHPHARMA.BO trades at ₹987.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas ORCHPHARMA.BO's P/E ratio is 67.66. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, ERIS.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check ORCHPHARMA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, BLISSGVS.NS has a market cap of 49.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while BLISSGVS.NS trades at ₹464.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas BLISSGVS.NS's P/E ratio is 38.56. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, ERIS.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check BLISSGVS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, BLISSGVS.BO has a market cap of 49.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while BLISSGVS.BO trades at ₹463.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas BLISSGVS.BO's P/E ratio is 38.47. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, ERIS.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check BLISSGVS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, RPGLIFE.BO has a market cap of 48.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while RPGLIFE.BO trades at ₹2,913.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas RPGLIFE.BO's P/E ratio is 41.83. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check RPGLIFE.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, RPGLIFE.NS has a market cap of 48.6B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while RPGLIFE.NS trades at ₹2,937.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas RPGLIFE.NS's P/E ratio is 42.17. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, ERIS.NS is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check RPGLIFE.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, IOLCP.BO has a market cap of 43.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while IOLCP.BO trades at ₹149.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas IOLCP.BO's P/E ratio is 29.29. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check IOLCP.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, IOLCP.NS has a market cap of 43.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while IOLCP.NS trades at ₹149.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas IOLCP.NS's P/E ratio is 29.37. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check IOLCP.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NOVARTIND.BO has a market cap of 40.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NOVARTIND.BO trades at ₹1,647.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NOVARTIND.BO's P/E ratio is 42.86. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check NOVARTIND.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, NOVARTIND.NS has a market cap of 40.1B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while NOVARTIND.NS trades at ₹1,641.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas NOVARTIND.NS's P/E ratio is 42.71. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, ERIS.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check NOVARTIND.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GUJTHEM.NS has a market cap of 39.3B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GUJTHEM.NS trades at ₹360.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GUJTHEM.NS's P/E ratio is 83.84. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, ERIS.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUJTHEM.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GUFICBIO.NS has a market cap of 38B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GUFICBIO.NS trades at ₹378.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GUFICBIO.NS's P/E ratio is 59.20. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUFICBIO.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, GUFICBIO.BO has a market cap of 38B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while GUFICBIO.BO trades at ₹378.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas GUFICBIO.BO's P/E ratio is 59.10. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check GUFICBIO.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, UNICHEMLAB.NS has a market cap of 37.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while UNICHEMLAB.NS trades at ₹537.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas UNICHEMLAB.NS's P/E ratio is 14.96. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check UNICHEMLAB.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, UNICHEMLAB.BO has a market cap of 37.8B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while UNICHEMLAB.BO trades at ₹539.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas UNICHEMLAB.BO's P/E ratio is 15.02. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, ERIS.NS is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check UNICHEMLAB.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AARTIDRUGS.NS has a market cap of 36.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AARTIDRUGS.NS trades at ₹404.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AARTIDRUGS.NS's P/E ratio is 19.04. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to AARTIDRUGS.NS. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIDRUGS.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, AARTIDRUGS.BO has a market cap of 36.9B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while AARTIDRUGS.BO trades at ₹404.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas AARTIDRUGS.BO's P/E ratio is 19.04. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, ERIS.NS is more volatile compared to AARTIDRUGS.BO. This indicates higher risk in terms of short-term price fluctuations for ERIS.NS.Check AARTIDRUGS.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, MOREPENLAB.BO has a market cap of 29.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while MOREPENLAB.BO trades at ₹53.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas MOREPENLAB.BO's P/E ratio is 31.09. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check MOREPENLAB.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, MOREPENLAB.NS has a market cap of 29.5B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while MOREPENLAB.NS trades at ₹53.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas MOREPENLAB.NS's P/E ratio is 28.62. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, ERIS.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check MOREPENLAB.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SOLARA.NS has a market cap of 23.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SOLARA.NS trades at ₹491.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SOLARA.NS's P/E ratio is 279.52. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, ERIS.NS is less volatile compared to SOLARA.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SOLARA.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, SOLARA.BO has a market cap of 23.7B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while SOLARA.BO trades at ₹490.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas SOLARA.BO's P/E ratio is 357.92. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to SOLARA.BO's ROE of -0.00%. Regarding short-term risk, ERIS.NS is less volatile compared to SOLARA.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check SOLARA.BO's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, INDOCO.NS has a market cap of 22.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while INDOCO.NS trades at ₹243.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas INDOCO.NS's P/E ratio is -17.30. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to INDOCO.NS's ROE of -0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to INDOCO.NS. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check INDOCO.NS's competition here

Eris Lifesciences Limited (NSE: ERIS.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ERIS.NS stands at 194.1B. In comparison, INDOCO.BO has a market cap of 22.4B. Regarding current trading prices, ERIS.NS is priced at ₹1,400.60 on the NSE, while INDOCO.BO trades at ₹242.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ERIS.NS currently has a P/E ratio of 39.62, whereas INDOCO.BO's P/E ratio is -23.26. In terms of profitability, ERIS.NS's ROE is +0.18%, compared to INDOCO.BO's ROE of -0.10%. Regarding short-term risk, ERIS.NS is less volatile compared to INDOCO.BO. This indicates lower risk in terms of short-term price fluctuations for ERIS.NS.Check INDOCO.BO's competition here